SHINE: Interim results - Later-onset SMA

CHERISH-SHINE interim results: Earlier SPINRAZA® treatment gives greatest benefit1

  • 125 patients with later-onset (Type II/III) SMA from CHERISH enrolled in SHINE1
  • At the interim analysis, the length of SPINRAZA® treatment ranged from 74 to 474 days (median: 250 days)1
  • A majority of patients experienced stabilisation or improvement in motor function1
  • The greatest benefit was seen with earlier initiation of SPINRAZA®1

Change in motor function and upper limb function from baseline to Day 265 in SHINE1

Bill
age 48*
Later-onset (Type III) SMA
treated with SPINRAZA®

*Age at time of photo shoot.

References:
1. SPINRAZA® Summary of Product Characteristics.